NCT04348500View on ClinicalTrials.gov

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
COVID-19
Interventions
DRUG

Clazakizumab

IV Infusion

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER

NCT04348500 - Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter